Screening for the High-risk Foot of Ulceration: Tests of Somatic and Autonomic Nerve Function

被引:10
作者
Argiana, Vasiliki [1 ]
Eleftheriadou, Ioanna [1 ]
Tentolouris, Nicholas [1 ]
机构
[1] Univ Athens, Sch Med, Dept Propaedeut & Internal Med 1, GR-11527 Athens, Greece
关键词
Diabetes; Foot ulceration; Peripheral neuropathy; Autonomic neuropathy; Tests; Somatic nerve function; Autonomic nerve function; VIBRATION PERCEPTION THRESHOLD; DIABETIC-NEUROPATHY; INDICATOR TEST; PERIPHERAL NEUROPATHY; SUDOMOTOR DYSFUNCTION; CLINICAL EXAMINATION; ALL-CAUSE; DIAGNOSIS; CARE; MONOFILAMENT;
D O I
10.1007/s11892-011-0192-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic foot ulcers affect almost 5% of the patients with diabetes and carry a huge physical, emotional, and financial burden. Almost 80% of amputations in patients with diabetes are preceded by a foot ulcer. The need for simple screening methods for prevention of foot ulcers and amputations is indisputable. Simple tests such as monofilament, tuning fork, vibration perception threshold determination, ankle reflexes, and pinprick sensation alone or in combination have been studied prospectively and can be used for identification of patients at risk. Newer tests examining sudomotor dysfunction and skin dryness have been introduced in recent years. In cross-sectional studies sudomotor dysfunction assessed by either sympathetic skin response or NEUROPAD (TM) (Miro Verbandstoffe GmbH, Wiehl-Drabenderhohe, Germany) testing has been consistently associated with foot ulceration. In addition, NEUROPAD (TM) testing is simple, reproducible, and widely available and has a high sensitivity for the diagnosis of clinical or subclinical diabetic polyneuropathy. Prospective studies are required to establish whether sudomotor dysfunction can predict foot ulcers and if simple methods assessing sudomotor dysfunction (eg, NEUROPAD (TM) testing) can be included in the screening tests for the prevention of this complication.
引用
收藏
页码:294 / 301
页数:8
相关论文
共 54 条
[1]   The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort [J].
Abbott, CA ;
Carrington, AL ;
Ashe, H ;
Bath, S ;
Every, LC ;
Griffiths, J ;
Hann, AW ;
Hussein, A ;
Jackson, N ;
Johnson, KE ;
Ryder, CH ;
Torkington, R ;
Van Ross, ERE ;
Whalley, AM ;
Widdows, P ;
Williamson, S ;
Boulton, AJM .
DIABETIC MEDICINE, 2002, 19 (05) :377-384
[2]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[3]  
[Anonymous], 1995, DIABETES CARE S1, DOI DOI 10.2337/DIACARE.18.1.S59
[4]   The 10-g monofilament - The diagnostic divining rod for the diabetic foot? [J].
Armstrong, DG .
DIABETES CARE, 2000, 23 (07) :887-887
[5]   Differences in the performance of commercially available 10-g monofilaments [J].
Booth, J ;
Young, MJ .
DIABETES CARE, 2000, 23 (07) :984-988
[6]   The global burden of diabetic foot disease [J].
Boulton, AJM ;
Vileikyte, L ;
Ragnarson-Tennvall, G ;
Apelqvist, J .
LANCET, 2005, 366 (9498) :1719-1724
[7]   Diabetic neuropathies - A statement by the American Diabetes Association [J].
Boulton, AJM ;
Vinik, AI ;
Arezzo, JC ;
Bril, V ;
Feldman, EL ;
Freeman, R ;
Malik, RA ;
Maser, RE ;
Sosenko, JM ;
Ziegler, D .
DIABETES CARE, 2005, 28 (04) :956-962
[8]  
Boulton AJM, 1998, DIABETIC MED, V15, pS57, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S57::AID-DIA741>3.3.CO
[9]  
2-4
[10]   Diabetic somatic neuropathies [J].
Boulton, AJM ;
Malik, RA ;
Arezzo, JC ;
Sosenko, JM .
DIABETES CARE, 2004, 27 (06) :1458-1486